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Abnormally Differentiating Keratinocytes in the
Epidermis of Systemic Sclerosis Patients Show
Enhanced Secretion of CCN2 and S100A9
Joanna Nikitorowicz-Buniak1, Xu Shiwen1, Christopher P. Denton1, David Abraham1 and Richard Stratton1
Skin involvement with dermal fibrosis is a hallmark of systemic sclerosis (SSc), and keratinocytes may be critical
regulators of fibroblast function through secretion of chemo-attracting agents, as well as through growth factors
and cytokines influencing the phenotype and proliferation rate of fibroblasts. Epithelial–fibroblast interactions
have an important role in fibrosis in general. We have characterized the SSc epidermis and asked whether SSc-
injured epidermal cells release factors capable of promoting fibrosis. Our results show that the SSc epidermis is
hypertrophic, and has altered expression of terminal differentiation markers involucrin, loricrin, and filaggrin.
Multiplex profiling revealed that SSc epidermal explants release increased levels of CCN2 and S100A9. CCN2
induction was found to spread into the upper papillary dermis, whereas S100A9 was shown to induce fibroblast
proliferation and to enhance fibroblast CCN2 expression via Toll-like receptor 4. These data suggest that the SSc
epidermis provides an important source of pro-fibrotic CCN2 and proinflammatory S100A9 in SSc skin, and
therefore contributes to the fibrosis and inflammation seen in the disease.
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INTRODUCTION
Systemic sclerosis (SSc) is a rheumatic connective tissue
disorder of unknown etiology and its common features include
autoimmunity, inflammation, and vasculopathy, leading
to fibrosis (Kahaleh and LeRoy, 1999). Central to SSc patho-
genesis is fibroblast activation (Jimenez and Bashey, 1977;
Abraham et al., 2007), which in SSc lesions persist as
myofibroblasts, with enhanced ability to produce collagens,
adhere, and contract extracellular matrix (ECM) (Jimenez et al.,
1986). Although the majority of studies were performed on the
dermis, there is increasing evidence supporting a key role for
the epidermis in promoting dermal fibrosis (Niessen et al.,
2001; Funayama et al., 2003; Bellemare et al., 2005; Meyer
et al., 2011; Mustoe and Gurjala, 2011; Simon et al., 2011).
Epithelial cells during tissue repair can stimulate fibroblasts
via IL-1 (Maas-Szabowski and Fusenig, 1996) to secrete
growth factors and cytokines essential for epithelial cell
growth (Smola et al., 1993). The keratinocytes can also
regulate fibroblast expression of ECM-modulating genes such
as CCN2, collagen type I, and fibronectin (Ghaffari et al.,
2009; Koskela et al., 2010). In co-cultures with epithelial cells,
fibroblasts contract more readily compared with those in the
monolayers (Shephard et al., 2004). The correct epithelial–
mesenchymal interactions are essential for skin homeostasis
(Maas-Szabowski et al., 2000; Szabowski et al., 2000) and
repair (El Ghalbzouri and Ponec, 2004; Werner et al., 2007).
These interactions are based on the production of soluble
factors (Smola et al., 1993; Ghahary et al., 2004; Denton
et al., 2009) and cell–matrix interactions (Gailit and Clark,
1994; Watt and Fujiwara, 2011).
Previous data from our group have shown the presence of
activated keratinocytes in the SSc epidermis (Aden et al., 2008)
and ability of the SSc epidermis to promote fibroblast activa-
tion and fibroblast CCN2 expression via epidermal-derived
IL-1a (Aden et al., 2010). Moreover, we have demonstrated the
activation of stress-induced mitogen-activated protein kinases
in the SSc epidermis. Therefore, we hypothesized that acti-
vated keratinocytes in the SSc epidermis have an important
role in propagation of skin fibrosis by releasing proinflam-
matory mediators and stimulating underlying fibroblasts. In this
report, we further define the altered differentiation in SSc
epidermis and profile the secreted growth factors and cytokines
from explant cultures of SSc and control epidermis.
RESULTS
Epidermal thickness and terminal differentiation markers
Although dermal thickness is increased in SSc, reports on
epidermal thickness are not consistent (Morley et al., 1985;
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Rossi et al., 2010; Van Praet et al., 2011). Therefore, to
assess the extent of the SSc epidermal thickness, histological
studies were performed on full-thickness skin biopsies. The
assessment revealed that the epidermis in the majority of
SSc sections contained more layers of cells when compared
with control tissue (Figure 1a). High-powered fields for each
epidermis of six controls and six patients were measured
(Figure 1b), showing a significant increase (P¼0.023) in the
median thickness of the SSc epidermis. In some SSc sections,
nucleated cells were still present within the stratum corneum
indicating parakeratosis (Figure 1a). Moreover, the cornified
layers of these biopsies had tightly packed corneocytes,
whereas in healthy epidermis corneocytes were spaced and
individual cells could be recognized. The findings were
consistent across early and established diffuse cutaneous SSc.
Therefore, to assess the differentiation process, sections
were stained with antibodies against classical terminal
differentiation markers involucrin, loricrin, and fillagrin.
In the SSc epidermis these markers formed thicker bands
compared with those in healthy control skin (Figure 1c, e, g).
When quantified, the mean depths of these proteins were
increased over twofold in the SSc epidermis. Moreover,
loricrin along with involucrin and filaggrin appeared in
relatively lower epidermal layers during differentiation of
SSc epidermal keratinocytes.
Keratinocyte hypertrophy and proliferation
We wanted to establish whether the thickened epidermis
contained more and/or larger cells. The number of cells
(Figure 2a) observed in the SSc epidermis was significantly
higher compared with those in healthy subjects (P¼0.004).
Cell areas of basal (Figure 2b) and spinous layer keratinocytes
(Figure 2c) were also significantly increased in SSc compared
with controls (P¼0.02 and P¼0.012).
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Figure 1. Abnormal terminal differentiation in the epidermis of systemic sclerosis (SSc) patients. (a) Control and SSc skin sections were stained with hematoxylin.
Parakeratosis in the SSc stratum corneum (SC) is marked with arrows. The expression of differentiation markers in the epidermis of SSc patients and controls was
detected by immunohistochemical staining using (c) anti-involucrin, (e) anti-loricrin, and (g) anti-filaggrin antibodies. Sections were counterstained with
hematoxylin and representative images chosen to analyze (b) the thickness of the SSc epidermis from the basal to the cornified layer (healthy control (HC) n¼ 6,
SSc n¼ 6) and expression bands of (d) involucrin (HC n¼ 5, SSc n¼ 7), (f) loricrin (HC n¼ 6, SSc n¼9), and (h) the thickness of filaggrin (HC n¼ 5, SSc n¼ 7). The
mean thickness for each band was calculated from 10 measurements taken from each section; bar¼ 20 mm. The results are presented as mean±SEM. Statistical
significance was determined using the Mann–Whitney U test; *Pp0.05, **Pp0.0005.
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Because the epidermal layer has significantly more and
larger keratinocytes, there may be more proliferation occur-
ring in SSc. In order to compare proliferation levels between
normal and SSc epidermal keratinocytes, sections were
stained with a marker of proliferation, ki-67 (Figure 2d). A
trend toward an increased number of positive cells was
observed in the SSc epidermis (P¼ 0.253) when compared
with healthy subjects (Figure 2e), suggesting greater activation
of keratinocytes in SSc.
Skin explant–conditioned media
Injured epidermal cells are known to secrete proinflammatory
cytokines and chemokines (Luger and Schwarz, 1990), as well
as growth factors affecting phenotype and proliferation of
dermal fibroblasts (Werner et al., 2007). To assess differences
in the release of key soluble factors, epidermal and
dermal explants were incubated overnight in serum-free
media, and their concentration measured using Luminex
(Austin, TX) and ELISA. The SSc epidermis demonstrated
significantly increased levels of CCN2 (P¼0.017),
hepatocyte growth factor (HGF) (P¼ 0.002), and S100A9
(P¼ 0.04) (Figure 3). Therefore, these molecules were selected
for further investigation.
Expression of CCN2, HGF, and S100A9 in the skin
As enhanced levels of CCN2, HGF, and S100A9 are released
into the conditioned media by the SSc epidermis, we per-
formed immunohistochemical analysis on human tissue sec-
tions (Figure 4). In healthy controls, positive staining for CCN2
(Figure 4a) was mainly limited to the epidermis, whereas
blood vessels and basal membrane showed only weak stain-
ing. In contrast, SSc sections showed pronounced staining
in the epidermis, epithelial/dermal junction (Figure 4i), and
around blood vessels (Figure 4ii). Interestingly, more CCN2
was present at the epidermal junction in early disease. At a
later stage it was present in the reticular dermis, especially
around the vasculature as well as in the epidermis.
The HGF staining maintained a very different pattern
compared with CCN2, with stronger staining (Figure 4b)
in healthy epidermis compared with SSc and no changes at
the epidermal–dermal junction (Figure 4i). However, more
HGF-positive cells were present in the SSc dermis (Figure 4ii)
than in controls. There was no staining in or around the
vasculature. No differences in staining pattern were observed
between early and established disease.
S100A9 is usually found as a dimer with S100A8; therefore,
immunofluorescent staining was used to determine the loca-
tion of S100A9 and its heterodimer partner in skin sections.
Staining confirmed elevated expression of S100A9 in the SSc
epidermis when compared with control subjects (Figure 5a).
The signal was observed throughout the SSc epidermis,
whereas in healthy skin it was present only in some epidermal
appendages. S100A8 staining was observed only in the
most superficial parts of the SSc epidermis. Single cells were
double labeled in the dermis in control and diseased tissue.
CCN2, S100A9, and S100A8 mRNA in epidermal blister sheets
As we had found increased CCN2 and S100A9, but not
S100A8, in the SSc epidermis as judged by immunohisto-
chemistry, we investigated whether the levels of mRNA for
these proteins were also altered. Results of blister epidermal
sheet analysis were consistent with the staining, showing
significant increase in CCN2 mRNA levels in the diffuse
cutaneous SSc epidermis (P¼ 0.03) (Figure 5b). Conversely,
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Figure 2. Activated keratinocytes in the systemic sclerosis (SSc) epidermis. (a) Number of keratinocytes and an average area of the cells in (b) the basal
and (c) spinous epidermal layers were measured in both SSc and control epidermis (healthy control (HC) n¼ 5, SSc n¼ 6). (d) The expression of proliferating cells
in the epidermis of SSc patients and controls was detected by immunohistochemical staining using anti-ki-67 antibody (HC n¼ 5, SSc n¼ 6); bar¼ 20 mm. (e) The
mean percentage of proliferating cells was calculated from an average of six measurements of ki-67-positive cells taken from each section, divided by the total
number of cells in the basal layer (HC n¼ 5, SSc n¼ 6). The results are presented as mean±SEM. Statistical significance was determined using the
Mann–Whitney U test; *Pp0.05, **Pp0.005.
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no difference was observed in the levels of S100A8 mRNA
(Figure 5c). However, a trend toward higher levels of S100A9
mRNA in the localized cutaneous SSc epidermis was observed
(Figure 5d). HGF mRNA was not detected (data not shown),
suggesting that the increased HGF protein released from
epidermal explants is not being transcribed locally.
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Figure 3. Increased concentration of CCN2, S100A9, and hepatocyte growth factor (HGF) in systemic sclerosis (SSc) epidermis–conditioned media. Forearm
biopsies were taken from SSc patients and matched controls. The epidermis and dermis were separated at the basal membrane using trypsin/EDTA and the
explants were incubated in serum-free media overnight. The conditioned media were then collected and used for analysis of selected soluble factors by ELISA
and Luminex platform. An increased concentration in SSc epidermis–conditioned media compared with control (Ctrl) was detected with (a) CCN2 (healthy
control (HC) n¼8, SSc n¼ 8), (b) HGF (HC n¼12, SSc n¼12), and (c) S100A9 (HC n¼6, SSc n¼ 6). No significant increase was detected in the levels of
(d) platelet-derived growth factor (PDGF)-AA (HC n¼6, SSc n¼ 6), (e) vascular endothelial growth factor (VEGF)-A (HC n¼12, SSc n¼ 12), (f) G-CSF (HC n¼ 12,
SSc n¼ 12), (g) fibroblast growth factor-2 (HC n¼ 12, SSc n¼ 12), (h) CCL20 (HC n¼12, SSc n¼ 12), (i) monocyte chemotactic protein-1 (MCP-1) (HC n¼12, SSc
n¼ 12), (j) IL-1a (HC n¼12, SSc n¼12), (k) IL-1b (HC n¼ 12, SSc n¼12), (l) IL-1ra (HC n¼ 12, SSc n¼ 12), (m) IL-6 (HC n¼6, SSc n¼ 6), (n) IL-8 (HC n¼ 6, SSc
n¼ 6), and (o) lactate dehydrogenase (LDH). The results are presented as mean±SEM. Statistical significance was determined using the Mann–Whitney U-test
*Pp0.05.
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Effects of rhS100A9 on dermal fibroblasts
S100A9 has been shown to signal through Toll-like receptor 4
(TLR4) and receptor for advanced glycation endproducts
(RAGE), and both pathways potentially contribute to CCN2
production. Therefore, we wanted to establish whether
S100A9 has an effect on fibroblasts and their CCN2 release.
An increase in proliferation of SSc fibroblasts (Figure 6a) and
migration of control and SSc fibroblasts (Figure 6b) was
observed in response to rhS100A9 when compared with
untreated cells (P¼ 0.03, P¼0.02, and P¼0.05, respectively).
In addition, rhS100A9 caused induction of CCN2 mRNA in
both healthy controls and SSc fibroblasts (P¼0.025 and
P¼0.047, respectively) (Figure 6c). Moreover, increased
CCN2 protein was demonstrated in response to S100A9
for SSc, but not for normal fibroblasts (Figure 6d, e). The
stimulation of CCN2 mRNA and protein production by
S100A9 was abolished after blocking the TLR4 with TAK-
242 inhibitor (Figure 6f–h).
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Figure 4. Increased expression of CCN2 in the systemic sclerosis (SSc) epidermis and at the epidermal–dermal junction in early SSc. The expression of
(a) CCN2 in the epidermis of early and established SSc patients and controls (Ctrl) was detected by immunohistochemical staining using anti-CCN2 antibody.
Panels show a magnified view of (i) the epidermal–dermal junction and (ii) blood vessels. Anti-hepatocyte growth factor (HGF) antibody was used for the
detection of (b) HGF in the skin. Magnified view of (i) the epidermis–dermis junction and (ii) the dermis. Sections were counterstained with hematoxylin and
representative images chosen.
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DISCUSSION
The mechanisms underlying the initiation and progression of
fibrotic changes in SSc remain poorly understood. Increasing
evidence suggests an important role for the epidermis in tissue
homeostasis, wound healing, and skin fibrosis (Niessen et al.,
2001; Funayama et al., 2003; Bellemare et al., 2005;
Mukhopadhyay et al., 2005; Aden et al., 2010; Simon et al.,
2011). In the present study, we observed a significant increase
in epidermal thickness between the basal layer and stratum
corneum, confirming previous reports (Rossi et al., 2010; Van
Praet et al., 2011). In a normal environment, the equilibrium
between epithelial cell proliferation and rate of terminal
differentiation contributes to the overall epidermal thickness,
and proliferation at the basal layer is precisely balanced
with desquamation in the cornified layer. Given the
increased thickness in SSc skin, we sought to assess these
two processes to determine whether increased proliferation
or altered terminal differentiation was occurring.
As in previous reports (Maeda et al., 1993; Van Praet et al.,
2011), presence of nuclei in the SSc stratum corneum
(parakeratosis) was observed in some of the SSc sections. In
addition, we found expression of key structural cornified-
envelope proteins involucrin, loricrin, and fillagrin to be much
lower in the SSc epidermis compared with healthy subjects.
They formed significantly thicker bands of expression, which
along with parakaretosis and atypical tightly packed stratum
corneum suggest delay in the final stages of the terminal
differentiation process—i.e., moving from the granular layer to
the stratum corneum. Such incomplete differentiation could
contribute to the thickening of the epidermis seen in the
disease and could be linked to cell activation.
A higher number of keratinocytes with a trend toward
increase in proliferation marker ki-67 in SSc could also
contribute to the increase in the SSc epidermal thickness.
Previous reports regarding proliferation of keratinocytes in SSc
skin are inconsistent and include hyperplasia (Milano et al.,
2008), nonsignificant increase in the number of proliferating
cells (Pablos et al., 1999), as well as epidermal atrophy
(Cooper et al., 1979). However, the discrepancies between
these results may be because of the differences in the charac-
teristics of recruited patients, such as disease duration, skin
score, or age, as well as because of the subset of SSc patients
used in the study (Milano et al., 2008). The significant
enlargement of keratinocytes in the basal and spinous layers
may also contribute to the increased thickness. Keratinocyte
size is known to influence its differentiation status; smaller
size is associated with DNA synthesis and inhibition of
differentiation, and larger size with differentiation promotion
(Watt and Green, 1981). The presented evidence suggests
disrupted terminal differentiation of SSc keratinocytes and
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supports a previous report from our group showing abnormal
expression of CK14 and CK1/CK10 in SSc epidermis (Aden
et al., 2008).
One of the explanations for the abnormal differentiation in
the SSc epidermis could be a change in the epidermal–dermal
interactions caused by differential expression of growth factors
and cytokines or contact with fibrotic ECM of the dermis.
Therefore, we sought to investigate the release of selected
proteins by epidermal and dermal cells. We found that the SSc
epidermis secreted significantly higher amounts of CCN2,
HGF, and S100A9 compared with control, whereas the SSc
dermis released significantly higher levels of HGF compared
with the control dermis. The data presented illustrate that
the SSc epidermis is able to release soluble factors relevant
to SSc pathogenesis and may be important in the generation
and maintenance of the disease.
CCN2 is responsible for stimulation of fibroblast growth,
myofibroblast differentiation (Grotendorst et al., 2004), matrix
production, and granulation tissue formation, and is
considered a key factor driving fibrosis in SSc (Frazier et al.,
1996). CCN2 is overexpressed in the majority of fibrotic
diseases including SSc, where increased serum, plasma, and
dermal interstitial fluid levels are associated with severity of
skin disease and disease duration (Sato et al., 2000). Further-
more, the CCN2 gene, primarily regulated by transforming
growth factor-beta at transcriptional level, is overexpressed
in SSc skin and lung fibroblasts (de Shi-Wen et al., 2008;
de Winter et al., 2008). Here we show that this critical
factor for maintenance of fibrosis is also upregulated in the
SSc epidermis. A higher concentration of CCN2 was
detected in the SSc epidermal explant–conditioned media
and CCN2 mRNA was increased in the epidermal blisters of
SSc patients. These findings were confirmed by enhanced
staining in the SSc epidermis, at the epidermal–dermal
junction in early disease, and around blood vessels, further
strengthening the evidence of increased CCN2 production
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by the SSc epidermis and epidermal contribution to the
disease.
HGF is produced by mesenchymal cells, and upon injury
become cleaved to a mature biologically active form, which
binds to the c-Met receptor on epithelial cells, enhancing
proliferation and migration to enable wound closure. How-
ever, HGF can also act in an autocrine manner, when released
by epithelial cells, as in certain types of cancer and extensive
skin injury (Nayeri et al., 2006). Keratinocytes overexpressing
HGF are hyperproliferative and form a thickened epidermis
(Hamoen and Morgan, 2002). HGF can be regarded as
an anti-fibrotic agent because of its ability to suppress
collagen synthesis and CCN2 in SSc fibroblasts (Jinnin et al.,
2005; Sherriff-Tadano et al., 2006; Bogatkevich et al., 2007).
Previous works showed enhanced HGF levels in SSc patients’
serum (Beirne et al., 2009), increased mRNA levels in SSc skin
(Frost et al., 2012), and amplified expression in SSc fibroblasts
along with its receptor c-Met (Kawaguchi et al., 2002). Results
from our group demonstrated increased c-Met phosphory-
lation in the SSc epidermis (Aden et al., 2010). Although this
report shows significantly raised HGF in the conditioned
media from the SSc epidermis compared with controls,
immunostaining and mRNA analysis suggest that keratino-
cytes might not be an important source of HGF in SSc skin.
The results indicate that the local fibroblasts might
be responsible for the overproduction, and keratinocytes
are a target. However, the increased presence of this anti-
differentiation factor could contribute to delayed differen-
tiation of SSc keratinocytes seen in the disease.
S100A9 belongs to a family of calcium-binding S100
proteins and its overexpression is seen in suprabasal keratino-
cytes of inflamed hyperproliferative, abnormally differentiated
epidermis (Benoit et al., 2006), certain types of cancers, and
inflammatory skin diseases such as lupus erythematosus.
Therefore, its high levels might be also responsible for the
abnormal differentiation of SSc keratinocytes. Moreover,
S100A9 known to be induced in keratinocytes during
epidermal stress is a damage-associated molecular pattern
molecule recognized by immune cells (Thorey et al., 2001;
Dazard et al., 2003; Marionnet et al., 2003). S100A9 secretion
stimulates the expression of IL-8, IL-6, and other proinflam-
matory cytokines, which then via a positive feedback loop
further stimulate the release of S100A9 and perpetuate
pathological changes (Nukui et al., 2008).
Here we demonstrate higher concentrations of S100A9
released by the SSc epidermis. This was further confirmed by
immunofluorescent staining, which revealed S100A9 expres-
sion in the basal and suprabasal SSc epidermis in contrast to
just weak basal expression in the control epidermis, and only
single cells stained in the dermis, therefore pointing at kerati-
nocytes as the main source of this protein in the SSc skin.
Results of the epidermal blister sheet analysis further confirmed
increase in S100A9 mRNA in the SSc epidermis. No differences
in S100A8 mRNA or protein levels were found, suggesting that
in SSc skin S100A9 does not heterodimerize with S100A8.
Although the role of S100A9 in SSc is unknown, recent
publications suggest its importance in the development of
disease. S100A9 has been shown to signal via TLR4 and
RAGE, and both pathways contribute to CCN2 production.
Moreover, overexpression of both RAGE (Davies et al., 2009)
and TLR4 (Bhattacharyya et al., 2013) was previously reported
in SSc skin. Recently, S100A9 was reported to promote lung
fibroblast activation via the RAGE pathway (Xu et al., 2013a),
whereas enhanced TLR4 signaling seems to sensitize
fibroblasts to pro-fibrotic stimulation by transforming growth
factor-beta1, a widely accepted factor in SSc pathogenesis
(Bhattacharyya et al., 2013). Furthermore, increased levels of
S100A9 were found in SSc skin and plasma (Xu et al., 2013b),
serum, feces, and saliva of SSc patients (Giusti et al., 2007;
Andreasson et al., 2011). Recently, S100A8/S100A9 was also
reported to be produced by activated keratinocytes of
fibroblast growth factor receptor knockout mouse and
identified as a key player in the development of dermal
fibrosis in these mice (Meyer et al., 2011). Furthermore,
S100A9 was also reported to stimulate fibroblast prolife-
ration and inhibit ECM degradation (Shibata et al., 2004).
Therefore, we wanted to establish whether S100A9 has a
direct effect on SSc fibroblasts.
Our results have shown that S100A9 stimulates proliferation
and migration of SSc dermal fibroblasts, and induces CCN2
protein and mRNA via TLR4 in cultured dermal fibroblasts
from both SSc and control. This is an important finding
suggesting a link between proinflammatory and pro-fibrotic
pathways that may have a role in SSc pathogenesis. It
emphasizes the potential for epithelial damage or activation
to modulate dermal fibroblast properties by induction of key
growth factors, and demonstrates the importance of inter-
actions of epidermal keratinocytes with dermal fibroblasts.
Implication of the TLR4-dependent pathway provides a link
between damage signal and involvement of the innate
immune system profoundly linked to fibrosis.
MATERIALS AND METHODS
Clinical materials
All SSc patients used in this report fulfilled the American College of
Rheumatology preliminary criteria for disease and were classified into
diffuse cutaneous SSc and limited cutaneous SSc according to
internationally accepted criteria (LeRoy et al., 1988). Samples were
classified as early SSc if within the first 2 years of disease onset,
defined by the appearance of the first non-Raynaud’s manifestation.
Patients with disease duration above 2 years were classified as
established. All patients and healthy volunteers gave written infor-
med consent to participate in the study (summary characteristics of
patients in Supplementary Table S1 online), which was conducted in
adherence to the Helsinki guidelines. The protocol used for collection
of epidermal blister sheets is described in the Supplementary
Materials and Methods online.
Immunohistochemistry
The antibodies and histological analysis used in this study are
described in the Supplementary Materials and Methods online.
Skin explant culture
The detailed protocol used to profile growth factors cytokines and
chemokines from the forearm biopsies is given in the Supplementary
Materials and Methods online.
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Incubation of fibroblasts with S100A9
The detailed protocol used in this study is given in Supplementary
Materials and Methods online.
RNA isolation and quantitative reverse transcriptase–PCR
Detailed quantitative real-time reverse-transcriptase–PCR protocol is
provided in Supplementary Materials and Methods online. Primer
sequences are listed in the Supplementary Table S3 online.
Statistical analysis
The data were analyzed using Excel (Microsoft, Redmond, WA) and
GraphPad Prim 5 (La Jolla, CA) software. The statistical significance
was assessed by the nonparametric Mann–Whitney test or the paired
t-test. Pp0.05 was considered as statistically significant.
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